


Amendment to the Claims:

This listing of claims will replace all prior versions and listing of claims in the application.

1. (Cancelled)
2. (Currently Amended) A compound of formula I



~~and the or a pharmaceutically acceptable salts, esters and tautomers~~ salt, ester or tautomer thereof, wherein

R^1 is selected from the group consisting of:

- (a) $-CF_3$,
- (b) $-CH_2C(CH_3)_3$,
- (c) phenyl, unsubstituted, mono- or poly- substituted with halo,
- (d) $-C_{1-6}$ alkyl, and
- (e) $-C_{1-2}$ alkyl-phenyl;


R^2 is selected from the group consisting of:

- (a) $-C_{1-6}$ alkyl,
- (b) $-COOR^3$,
- (c) $-CR^3R^4-O-R^5$,
- (d) $-CR^3R^4-S-R^5$, and
- (e) $-COR^3$;


R^3 , R^4 and R^5 are independently selected at each occurrence from the group consisting of $-H$, phenyl, and C_{1-6} alkyl;

Y is joined together with the nitrogen and the carbonyl carbon shown in Formula I to which Y is respectively attached, to form a heterocyclic ring selected from:

- (a) a 5-membered heterocyclic ring selected from the group consisting of:




(b) a 6-membered heterocyclic ring selected from the group consisting of:








provided that when R¹ is -CF₃, R² is n-propyl, and Z is n-propyloxy, the 6-membered heterocyclic ring is not unsubstituted 5,6 dihydrouracil,

(c)



(d) a bicyclic heterocyclic ring selected from the group consisting of:



wherein each carbon atom in the heterocyclic ring, formed when Y is joined together with the nitrogen and the carbonyl carbon shown in Formula I, is independently unsubstituted, mono- or di- substituted with a substituent independently selected at each occurrence from R⁷;

R⁶ is independently selected at each occurrence from the group consisting of:

- (a) -H,
- (b) -C₁₋₆alkyl, unsubstituted, mono- or poly- substituted with a substituent selected from the group consisting of halo, -OH, -NR³R⁴, -OR³, -COOR³, and -CN,

- (c) $-C_{1-6}$ alkyl-phenyl, unsubstituted, mono- or poly- substituted with a substituent selected from the group consisting of halo, $-C_{1-3}$ alkyl, and $-COOR^3$,
- (d) $-C_{3-6}$ cycloalkyl, unsubstituted, mono- or poly- substituted with a substituent selected from the group consisting of halo, $-OH$, $-OR^3$, $-COOR^3$, and $-CN$,
- (e) $-C_{3-6}$ cycloheteroalkyl, unsubstituted, mono- or poly- substituted with a substituent selected from the group consisting of halo, $-OH$, $-(CH_2)_nOR^3$, $-OR^3$, $-COOR^3$, and $-CN$, wherein n is an integer selected from 2, 3, 4, 5 and 6,
- (f) $-C_{2-6}$ alkenyl,
- (g) $-C(O)C_{1-6}$ alkyl,
- (h) $-COOR^3$,
- (i) $-C(O)-(CH_2)_p-COOR^3$, wherein p is an integer selected from 2, 3 and 4,
- (j) phenyl, unsubstituted, mono- or poly- substituted with a substituent selected from the group consisting of halo, $-C_{1-3}$ alkyl, and $-COOR^3$,
- (k) pyridyl, unsubstituted, mono- or poly- substituted with a substituent selected from the group consisting of halo, $-C_{1-3}$ alkyl, and $-COOR^3$,
- (l) pyrimidinyl, unsubstituted, mono- or poly- substituted with a substituent selected from the group consisting of halo, $-C_{1-3}$ alkyl, and $-COOR^3$,
- (m) pyrazinyl, unsubstituted, mono- or poly- substituted with a substituent selected from the group consisting of halo, $-C_{1-3}$ alkyl, and $-COOR^3$, and
- (n) thiazolyl, unsubstituted, mono- or poly- substituted with a substituent selected from the group consisting of halo, $-C_{1-3}$ alkyl, and $-COOR^3$;

R^7 is independently selected at each occurrence from the group consisting of:

- (a) $=O$,
- (b) $-C_{1-6}$ alkyl-phenyl, unsubstituted, mono- or poly- substituted with a substituent selected from the group consisting of halo, $-CN$, $-COOR^3$, $-COR^3$, and $-OH$,
- (c) $-C_{1-6}$ alkyl, unsubstituted, mono- or poly- substituted with a substituent selected from the group consisting of halo, $-OH$, $-COOR^3$, tetrazole and $-CN$,
- (d) $-C_{3-6}$ cycloalkyl,
- (e) $-C_{3-6}$ spiroalkyl,
- (f) $-COOR^3$,
- (g) halo,
- (h) $-NR^3R^4$,
- (i) phenyl, unsubstituted, mono- or poly- substituted with a substituent selected from the group consisting of halo, $-COOR^3$ and $-C_{1-4}$ alkyl,
- (j) pyridyl, unsubstituted, mono- or poly- substituted with a substituent selected from the group consisting of halo, $-C_{1-3}$ alkyl, and $-COOR^3$,

- (k) pyrimidinyl, unsubstituted, mono- or poly- substituted with a substituent selected from the group consisting of halo, $-C_{1-3}$ alkyl, and $-COOR^3$, and
- (l) pyrazinyl, unsubstituted, mono- or poly- substituted with a substituent selected from the group consisting of halo, $-C_{1-3}$ alkyl, and $-COOR^3$; and

Z is selected from the group consisting of:

- (a) $-C_{1-6}$ alkyl-,
- (b) $-C_{1-6}$ alkyl-O-,
- (c) $-C_{3-6}$ cycloalkyl-, and
- (d) $-C_{3-6}$ cycloalkyl-O-;

and wherein the pharmaceutically acceptable ester of the compound of formula I is selected from the group consisting of (a) a phenyl ester, (b) a $-C_{1-6}$ alkyl ester and (c) a substituted C_{1-4} alkyl ester wherein the substituent is selected from the group consisting of phenyl-, dimethylamino- and acetylamino-.

3. (Previously presented) The compound of claim 2 wherein Z is $-C_{2-4}$ alkyl-O-.

4. (Original) The compound of claim 3 wherein

R^1 is selected from the group consisting of:

- (a) $-CF_3$,
- (b) $-CH_2C(CH_3)_3$, and
- (c) phenyl, unsubstituted, mono- or poly- substituted with halo; and


R^2 is selected from the group consisting of:

- (a) $-C_{1-6}$ alkyl, and
- (b) $-COR^3$.


5. (Original) The compound of claim 4 wherein R^2 is n-propyl.

6. (Original) The compound of claim 5 wherein Y is joined together with the nitrogen and the carbonyl carbon shown in Formula I to which Y is respectively attached, to form a heterocyclic ring selected from:


- (a) a 5-membered heterocyclic ring selected from the group consisting of:




(b) a 6-membered heterocyclic ring selected from the group consisting of:



(c)



(d)



wherein each carbon atom in the heterocyclic ring, formed when Y is joined together with the nitrogen and the carbonyl carbon shown in Formula I, is independently unsubstituted, mono- or di- substituted with a substituent independently selected at each occurrence from R⁷.

7. (Original) The compound of claim 6 wherein R⁶ is independently selected at each occurrence from the group consisting of:

- (a) -H,
- (b) -C₁₋₆alkyl, unsubstituted, mono- or poly- substituted with a substituent selected from the group consisting of halo, -OH, -NR³R⁴, -OR³, -COOR³, and -CN,
- (c) -C₁₋₆alkyl-phenyl, unsubstituted, mono- or poly- substituted with a substituent selected from the group consisting of halo, -C₁₋₃alkyl, and -COOR³,
- (d) -C(O)-(CH₂)_p-COOR³, wherein p is an integer selected from 2, 3 and 4,
- (e) phenyl, unsubstituted, mono- or poly- substituted with a substituent selected from the group consisting of halo, -C₁₋₃alkyl, and -COOR³,
- (f) pyridyl, unsubstituted, mono- or poly- substituted with a substituent selected from the group consisting of halo, -C₁₋₃alkyl, and -COOR³, and
- (g) pyrimidinyl, unsubstituted, mono- or poly- substituted with a substituent selected from the group consisting of halo, -C₁₋₃alkyl, and -COOR³.

8. (Original) The compound of claim 7 wherein R⁷ is independently selected from the group consisting of:

- (a) =O,
- (b) -CH₂-phenyl, unsubstituted, mono- or poly- substituted with a substituent selected from the group consisting of halo, -CN, -COOR³, -COR³, and -OH,
- (c) -C₁₋₆alkyl, unsubstituted, mono- or poly- substituted with a substituent selected from the group consisting of halo, -OH, -COOR³, tetrazole and -CN,
- (d) halo,
- (e) -NH₂,
- (f) phenyl, unsubstituted, mono- or poly- substituted with a substituent selected from the group consisting of halo, -COOR³ and -C₁₋₄alkyl, and


- (g) pyridyl, unsubstituted, mono- or poly- substituted with a substituent selected from the group consisting of halo, $-C_{1-3}$ alkyl, and $-COOR^3$.

9. (Original) The compound of claim 3 wherein R^1 is selected from the group consisting of:


- (a) $-CF_3$, and
 (b) phenyl, unsubstituted, mono- or poly- substituted with halo.

10. (Original) The compound of claim 9 wherein Y is joined together with the nitrogen and the carbonyl carbon shown in Formula I to which Y is respectively attached, to form a heterocyclic ring selected from:


- (a) a 5-membered heterocyclic ring selected from the group consisting of:




- (b) a 6-membered heterocyclic ring selected from the group consisting of:



- (c)



(d)




wherein each carbon atom in the heterocyclic ring, formed when Y is joined together with the nitrogen and the carbonyl carbon shown in Formula I, is independently unsubstituted, mono- or di- substituted with a substituent independently selected at each occurrence from R⁷.


11. (Original) The compound of claim 3 wherein R¹ is -CF₃.

12. (Original) The compound of claim 11 wherein Y is joined together with the nitrogen and the carbonyl carbon shown in Formula I to which Y is respectively attached, to form a heterocyclic ring selected from:

(a) a 5-membered heterocyclic ring selected from the group consisting of:



(b) a 6-membered heterocyclic ring selected from the group consisting of:



wherein each carbon atom in the heterocyclic ring, formed when Y is joined together with the nitrogen and the carbonyl carbon shown in Formula I, is independently unsubstituted, mono- or di- substituted with a substituent independently selected at each occurrence from R⁷.

13. (Previously presented) The compound of claim 2 wherein Z is -C₃₋₆cycloalkyl-O-.

14. (Previously presented) The compound of claim 2 wherein Z is -C₄-alkyl-.

15. (Currently amended) A compound selected from the group consisting of:

- (1) 1-(3-{{[7-propyl-3-(neopentyl)-1,2-benzisoxazol-6-yl]oxy}propyl})pyrrolidine-2,5-dione;
- (2) 1-(3-{{[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy}propyl})pyrrolidine-2,5-dione;
- (3) 2-(3-{{[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy}propyl})-1*H*-isoindole-1,3(2*H*)-dione;
- (4) 3,3-dimethyl-1-(3-{{[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy}propyl})pyrrolidine-2,5-dione;
- (5) 3-methyl-3-phenyl-1-(3-{{[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy}propyl})pyrrolidine-2,5-dione;
- (6) 3-(3-{{[7-propyl-3-(neopentyl)-1,2-benzisoxazol-6-yl]oxy}propyl})thiazolidine-2,4-dione;
- (7) 3-(3-{{[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy}propyl})thiazolidine-2,4-dione;
- (8) 5,5-dimethyl-3-(3-{{[7-propyl-3-(neopentyl)-1,2-benzisoxazol-6-yl]oxy}propyl})thiazolidine-2,4-dione;
- (9) [2,4-dioxo-3-(3-{{[7-propyl-3-(neopentyl)-1,2-benzisoxazol-6-yl]oxy}propyl})-1,3-thiazolidin-5-yl]acetic acid;
- (10) 3-(3-{{[7-propyl-3-(neopentyl)-1,2-benzisoxazol-6-yl]oxy}propyl})imidazolidine-2,4-dione;
- (11) 3-(3-{{[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy}propyl})imidazolidine-2,4-dione;
- (12) 1-methyl-3-(3-{{[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy}propyl})imidazolidine-2,4-dione;
- (13) 5(R)-methyl-3-(3-{{[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy}propyl})imidazolidine-2,4-dione;
- (14) 5,5-dimethyl-3-(3-{{[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy}propyl})imidazolidine-2,4-dione;
- (15) 1-(2-pyridyl)-3-(3-{{[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy}propyl})imidazolidine-2,4-dione;
- (16) 5-methyl-5-phenyl-3-(3-{{[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy}propyl})imidazolidine-2,4-dione;
- (17) 5-methyl-5-phenyl-3-(3-{{[7-propyl-3-(neopentyl)-1,2-benzisoxazol-6-yl]oxy}propyl})imidazolidine-2,4-dione;
- (18) 5-methyl-5-phenyl-3-(3-{{[7-propyl-3-(phenyl)-1,2-benzisoxazol-6-yl]oxy}propyl})imidazolidine-2,4-dione;
- (19) 5-methyl-5-phenyl-3-(3-{{[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy}butyl})imidazolidine-2,4-dione;

- (20) 5-methyl-5-(3-carboxyphenyl)-3-(3-{{[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy}propyl}imidazolidine-2,4-dione;
- (21) 5-methyl-5-(4-pyridyl)-3-(3-{{[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy}propyl}imidazolidine-2,4-dione;
- (22) 5-methyl-5-(3-pyridyl)-3-(3-{{[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy}propyl}imidazolidine-2,4-dione;
- (23) 5-methyl-5-(2-pyridyl)-3-(3-{{[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy}propyl}imidazolidine-2,4-dione;
- (24) 3-(3-{{[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy}propyl}-1-pyrimidin-2-ylimidazolidine-2,4-dione;
- (25) 3-(3-{{[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy}propyl}-1-pyrazin-2-ylimidazolidine-2,4-dione;
- (26) 3-[2,5-dioxo-4-phenyl-1-(3-{{[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy}propyl}imidazolidin-4-yl]propanoic acid;
- (27) 4-[5,5-dimethyl-2,4-dioxo-3-(3-{{[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy}propyl}imidazolidin-1-yl]butanoic acid;
- (28) 4-[5,5-dimethyl-2,4-dioxo-3-(3-{{[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy}propyl}imidazolidin-1-yl]pentanoic acid;
- (29) 1-(3-{{[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy}propyl}imidazolidin-2-one;
- (30) methyl 2-[2-oxo-3-(3-{{[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy}propyl}imidazolidin-1-yl]propanoate;
- (31) 2-[2-oxo-3-(3-{{[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy}propyl}imidazolidin-1-yl]propanoic acid;
- (32) 1-(3-{{[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy}propyl}imidazolidine-2,4-dione;
- (33) 5,5-dimethyl-1-(3-{{[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy}propyl}imidazolidine-2,4-dione;
- (34) 1-[*cis*-2-{{[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy}cyclohexyl)methyl]dihydropyrimidine-2,4(1*H*,3*H*)-dione;
- (35) 1-[*trans*-2-{{[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy}cyclopentyl)methyl]dihydropyrimidine-2,4(1*H*,3*H*)-dione;
- (36) 1-{4-[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]butyl}dihydropyrimidine-2,4(1*H*,3*H*)-dione;
- (37) 5-phenyl-3-(3-{{[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy}propyl}dihydropyrimidine-2,4(1*H*,3*H*)-dione;
- (38) 6-phenyl-3-(3-{{[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy}propyl}dihydropyrimidine-2,4(1*H*,3*H*)-dione;

- (39) 5-Methyl-3-(3-{[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy}propyl)dihydropyrimidine-2,4(1*H*,3*H*)-dione;
- (40) 1,5-Dimethyl-3-(3-{[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy}propyl)dihydropyrimidine-2,4(1*H*,3*H*)-dione;
- (41) 1-phenyl-3-(3-{[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy}propyl)dihydropyrimidine-2,4(1*H*,3*H*)-dione;
- (42) 3-(3-{[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy}propyl)-1-pyridin-2-yl)dihydropyrimidine-2,4(1*H*,3*H*)-dione;
- (43) 3-(3-{[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy}propyl)-5,6-dihydro-2*H*-1,2'-bipyrimidine-2,4(3*H*)-dione;
- (44) 3-(3-{[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy}propyl)-5,6-dihydro-2*H*-1,5'-bipyrimidine-2,4(3*H*)-dione;
- (45) 1-(3-{[7-propyl-3-(neopentyl)-1,2-benzisoxazol-6-yl]oxy}propyl)piperidin-2-one;
- (46) 1-(3-{[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy}propyl)piperidin-2-one;
- (47) 1-(3-{[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy}propyl)piperidin-2,6-dione;
- (48) 1-(3-{[7-propyl-3-(phenyl)-1,2-benzisoxazol-6-yl]oxy}propyl)piperidin-2,5-dione;
- (49) 4-(3-{[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy}propyl)morpholine-3,5-dione;
- (50) 1-(3-{[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy}propyl)piperazine-2,5-dione;
- (51) 4-(3-{[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy}propyl)piperazine-2-one;
- (52) 3-(3-{[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy}propyl)-1,3,5-triazinane-2,4-dione;
- (53) 3-(3-{[7-propyl-3-(phenyl)-1,2-benzisoxazol-6-yl]oxy}propyl)dihydropyrimidine-2,4(1*H*,3*H*)-dione;
- (54) 6-methyl-3-(3-{[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy}propyl)dihydropyrimidine-2,4(1*H*,3*H*)-dione; and
- (55) 1-(3-{[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy}propyl)azepan-2-one;

and pharmaceutically acceptable salts, esters and tautomers thereof, wherein the pharmaceutically acceptable esters are selected from the group consisting of (a) a phenyl ester, (b) a -C₁₋₆alkyl ester and (c) a substituted -C₁₋₄alkyl ester wherein the substituent is selected from the group consisting of phenyl-, dimethylamino- and acetylamino-.

16. (Cancelled)

17. (Previously presented) A method for treating dyslipidemia comprising administering a therapeutically effective amount of a compound of claim 2 to a patient in need thereof.

18. (Original) The method of claim 17 wherein the dyslipidemia comprises depressed plasma HDL cholesterol level.

19. (Previously presented) A method for treating atherosclerosis comprising administering a therapeutically effective amount of a compound of claim 2 to a patient in need thereof.

20-24. (Cancelled)

25. (Previously presented) A pharmaceutical composition comprised of a compound of claim 2 and a pharmaceutically acceptable carrier.

26-29. (Cancelled)

30. (Currently amended) The A compound according to Claim 2 selected from the group consisting of:

- (1) 11-(3-{[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy}propyl)imidazolidin-2-one;
- (2) 1-(3-{[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy}propyl)pyrrolidine-2,5-dione;
- (3) 3-(3-{[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy}propyl)thiazolidine-2,4-dione;
- (4) 3-(3-{[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy}propyl)imidazolidine-2,4-dione;
- (5) 1-Methyl-3-(3-{[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy}propyl)imidazolidine-2,4-dione;
- (6) 5,5-dimethyl-3-(3-{[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy}propyl)imidazolidine-2,4-dione;
- (7) 1-Phenyl-3-(3-{[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy}propyl)imidazolidine-2,4-dione;
- (8) 1-(2-pyridyl)-3-(3-{[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy}propyl)imidazolidine-2,4-dione;
- (9) 5-Phenyl-5-methyl-3-(3-{[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy}propyl)imidazolidine-2,4-dione;
- (10) 5-Phenyl-5-methyl-3-(3-{[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy}butyl)imidazolidine-2,4-dione;
- (11) 5-Phenyl-5-methyl-3-(3-{[7-propyl-3-(phenyl)-1,2-benzisoxazol-6-yl]oxy}propyl)imidazolidine-2,4-dione;
- (12) 5-(3-carboxyphenyl)-5-methyl-3-(3-{[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy}propyl)imidazolidine-2,4-dione;

- (13) 5-(2-Pyridyl)-5-methyl-3-(3-{{[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy}propyl}imidazolidine-2,4-dione;
- (14) 5-Phenyl-5-(3-propionyl)-3-(3-{{[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy}propyl}imidazolidine-2,4-dione;
- (15) 2-[2-oxo-3-(3-{{[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy}propyl}imidazolidin-1-yl]propanoic acid;
- (16) 1-(3-{{[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy}propyl}piperidin-2-one;
- (17) 1-(3-{{[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy}propyl}piperidin-2,6-dione;
- (18) 1-(3-{{[7-propyl-3-(phenyl)-1,2-benzisoxazol-6-yl]oxy}propyl}piperidin-2,5-dione;
- (19) 1-*[cis-2-{{[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy}cyclohexyl}methyl]* dihydropyrimidine-2,4(1*H*,3*H*)-dione;
- (20) 3-(3-{{[7-propyl-3-(phenyl)-1,2-benzisoxazol-6-yl]oxy}propyl}-dihydropyrimidine-2,4(1*H*,3*H*)-dione;
- (21) 6-phenyl-3-(3-{{[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy}propyl}dihydropyrimidine-2,4(1*H*,3*H*)-dione;
- (22) 1-phenyl-3-(3-{{[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy}propyl}dihydropyrimidine-2,4(1*H*,3*H*)-dione;
- (23) 3-(3-{{[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy}propyl}-1-pyridin-2-yl)dihydropyrimidine-2,4(1*H*,3*H*)-dione;
- (24) 3-(3-{{[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy}propyl}-5,6-dihydro-2*H*-1,2'-bipyrimidine-2,4(3*H*)-dione; and
- (25) 1-(3-{{[7-propyl-3-(trifluoromethyl)-1,2-benzisoxazol-6-yl]oxy}propyl}azepan-2-one,

and pharmaceutically acceptable salts, esters and tautomers thereof, wherein the pharmaceutically acceptable esters are selected from the group consisting of (a) a phenyl ester, (b) a -C₁₋₆alkyl ester and (c) a substituted -C₁₋₄alkyl ester wherein the substituent is selected from the group consisting of phenyl-, dimethylamino- and acetylamino-.